Table 2.
Mean Fluorescent Intensity of Prodigiosin, Daunorubicin, and Mitoxantrone in the Presence and Absence of Specific Multidrug Resistance Inhibitors After Efflux Period
|
Mean fluorescent intensity (MFI)±SE | |||||
|---|---|---|---|---|---|
| EPG85-257 | EPG85-257RDB | EPG85-257RNOV | A2780 | A2780RCIS | |
| Prodigiosin | 31.7±2.31 | 15.8±0.59 | 8.1±0.15 | 15.1±0.28 | 4.1±0.14 |
| Prodigiosin+Ver | 14.3±2.01 | 11.0±0.83 | ND | ND | ND |
| Prodigiosin+Indo | ND | ND | ND | 13.3±0.62 | 3.4±0.15 |
| Prodigiosin+Novo | 7.4±0.53 | ND | 6.7±0.35 | ND | ND |
| Daunorubicin | 134.1±4.11 | 5.6±0.61 | ND | 50.4±0.62 | 24.7±1.64 |
| Daunorubicin+Ver | 66.4±3.98 | 11.4±0.95 | ND | ND | ND |
| Daunorubicin+Indo | ND | ND | ND | 59.2±0.62 | 60.6±2.45 |
| Mitoxantrone | 185.5±5.12 | ND | 59.9±2.51 | ND | ND |
| Mitoxantrone+Novo | 111.9±2.91 | ND | 117.5±3.83 | ND | ND |
ND, not done.